Cilnidipine, a slow-acting Ca 2+ channel blocker, induces relaxation in porcine coronary artery: Role of endothelial nitric oxide and [Ca 2+] i

British Journal of Pharmacology

Volumn 147, Issue 1, 2006, Pages 55-63

  Hok, Sum Leung ^a   Yao, Xiaoqiang ^a   Fung, Ping Leung ^a   Wing, Hung Ko ^a   Chen, Zhen Yu ^a   Gollasch, Maik ^b   Huang, Yu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Arteries; Ca 2+ channel; Cilnidipine; Intracellular calcium; Nitric oxide

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ARGININE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OMEGA CONOTOXIN; POTASSIUM CHLORIDE; SCAVENGER;

ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG MECHANISM; EXTRACELLULAR CALCIUM; FLUORESCENCE; FORCE TRANSDUCER; IMAGING; ISOLATED ORGAN; NONHUMAN; PRIORITY JOURNAL; SWINE; TENSION; TIME; VASODILATATION;

ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CORONARY VESSELS; DIHYDROPYRIDINES; ENDOTHELIUM, VASCULAR; NIFEDIPINE; NITRIC OXIDE; SWINE; VASODILATION;

EID: 30344473630     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706450     Document Type: Article

References (32)

1. ADAMS, D.J., BARAKEH, J., LASKEY, R. & VAN BREEMEN, C. (1989). Ion channels and intracellular calcium in vascular endothelial cells. FASEB J., 3, 2389-2400.
2. BERKELS, R., EGINK, G., MARSEN, T.A., BARTELS, H., ROESEN, R. & KLAUS, W. (2001). Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension, 37, 240-245.
3. i and NO in endothelial cells. J. Cardiovasc. Pharmacol. Ther., 4, 175-181.
4. BLOIS, M.S. (1958). Antioxidant determination by the use of a stable free radical. Nature, 181, 1199-1200.
5. 2+ channel blockers on noradrenaline release and purinergic neuroeffector transmission in rat tail artery. Br. J. Pharmacol., 126, 11-18.
6. COMINACINI, L., FRATTA PASINI, A., GARBIN, U., PASTORINO, A.M., DAVOLI, A., NAVA, C., CAMPAGNOLA, M., ROSSATO, P. & LO CASCIO, V. (2003). Antioxidant activity of different dihydropyridines. Biochem. Biophys. Res. Commun., 302, 679-684.
7. DING, Y. & VAZIRI, N.D. (2000). Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J. Pharmacol. Exp. Ther., 292, 606-609.
8. ENCORE INVESTIGATORS. (2003). Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation, 107, 422-428.
9. ++ channel in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther., 280, 1184-1191.
10. FURBERG, C.D., PSATY, B.M. & MEYER, J.V. (1995). Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation, 92, 1326-1331.
11. HEMPEL, A., LINDSCHAU, C., MAASCH, C., MAHN, M., BYCHKOV, R., NOLL, T., LUFT, F.C. & HALLER, H. (1999). Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. Circulation, 99, 2523-2529.
12. HOSONO, M., FUJII, S., HIRUMA, T., WATANABE, K., HAYASHI, Y., OHNISHI, H., TAKATA, Y. & KATO, H. (1995). Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn. J. Pharmacol., 69, 127-134.
13. i signaling in intact rat aortic endothelium. FASEB J., 14, 797-804.
14. JULIUS, S. (1993). Sympathetic hyperactivity and coronary risk in hypertension. Hypertension, 21, 886-893.
15. KITAHARA, Y., SAITO, F., AKAO, M., FUJITA, H., TAKAHASHI, A., TAGUCHI, H., HINO, T., OTSUKA, Y., KUSHIRO, T. & KANMATSUSE, K. (2004). Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients. J. Cardiovasc. Pharmacol., 43, 68-73.
16. KRENEK, P., SALOMONE, S., KYSELOVIC, J., WIBO, M., MOREL, N. & GODFRAIND, T. (2001). Lacidipine prevents endothelial dysfunction in salt-loaded stroke-prone hypertensive rats. Hypertension, 37, 1124-1128.
17. KOBAYASHI, N., MORI, Y., MITA, S., NAKANO, S., KOBAYASHI, T., TSUBOKOU, Y. & MATSUOKA, H. (2001). Effects of cilnidipine on nitric oxide and endothelin-1 expression and extracellular signal-regulated kinase in hypertensive rats. Eur. J. Pharmacol., 422, 149-157.
18. LESNIK, P., DACHET, C., PETIT, L., MOREAU, M., GRIGLIO, S., BRUDI, P. & CHAPMAN, M.J. (1997). Impact of a combination of a calcium antagonist and a β-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Arterioscler. Thromb. Vasc. Biol., 17, 979-988.
19. LOHN, M., MUZZULINI, U., ESSIN, K., TSANG, S.Y., KIRSCH, T., LITTERAL, J., WALDRON, P., CONRAD, H., KLUGBAUER, N., HOFMANN, F., HALLER, H., LUFT, F.C., HUANG, Y. & GOLLASCH, M. (2002). Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C. J. Hypertens., 20, 885-893.
20. MINAMI, J., KAWANO, Y., MAKINO, Y., MATSUOKA, H. & TAKISHITA, S. (2000). Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension. Br. J. Clin. Pharmacol., 50, 615-620.
21. MINAMI, J., ISHIMITSU, T., KAWANO, Y., NUMABE, A. & MATSUOKA, H. (1998). Comparison of 24-h blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J. Cardiovasc. Pharmacol., 32, 331-336.
22. MOMBOULI, J.V. & VANHOUTTE, P.M. (1999). Endothelial dysfunction: from physiology to therapy. J. Mol. Cell Cardiol., 31, 61-74.
23. MURAD, F. (1994). The nitric oxide-cyclic GMP signal transduction system for intracellular and intercellular communication. Recent Prog. Horm. Res., 49, 239-248.
24. NAKAJIMA, M., YAMADA, S., UCHIDA, S. & KIMURA, R. (2002). In vivo measurement of 1,4-dihydropyridine receptors in mesenteric arteries of spontaneously hypertensive rats and effect of nifedipine and cilnidipine. Biol. Pharm. Bull., 25, 24-28.
25. PSATY, B.M., HECKBERT, S.R., KOEPSELL, T.D., SISCOVICK, D.S., RAGHUNATHAN, T.E., WEISS, N.S., ROSENDAAL, F.R., LEMAITRE, R.N., SMITH, N.L., WAHL, P.W., WAGNER, E.H. & FURBERG, C.D. (1995). The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA, 274, 620-625.
26. STASON, W.B., SCHMID, C.H., NIEDZWIECKI, D., WHITING, G.W., CAUBET, J.F., CORY, D., LUO, D., ROSS, S.D. & CHALMERS, T.C. (1999). Safety of nifedipine in angina pectoris: a meta-analysis. Hypertension, 33, 24-31.
27. TADDEI, S., VIRDIS, A., GHIADONI, L., ULERI, S., MAGAGNA, A. & SALVETTI, A. (1997). Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension, 30, 1606-1612.
28. TAKEDA, K., YAMAGISHI, R., MASUMIYA, H., TANAKA, H. & SHIGENOBU, K. (2004). Effect of cilnidipine on L- and T-type calcium currents in guinea pig ventricle and action potential in rabbit sinoatrial node. J. Pharmacol. Sci., 95, 398-401.
29. TOMINAGA, M., OHYA, Y., TSUKASHIMA, A., KOBAYASHI, K., TAKATA, Y., KOGA, T., YAMASHITA, Y., FUJISHIMA, Y., ABE, I. & FUJISHIMA, M. (1997). Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine. Cardiovasc. Drugs Ther., 11, 43-48.
30. VARAGIC, J., SUSIC, D. & FROHLICH, E.D. (2002). Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J. Hypertens., 20, 317-322.
31. YOSHIMOTO, R., DOHMOTO, H., YAMADA, K. & GOTO, A. (1991). Prolonged inhibition of vascular contraction and calcium influx by the novel 1,4-dihydropyridine calcium antagonist cinaldipine (FRC-8653). Jpn. J. Pharmacol., 56, 225-229.
32. ZHANG, X. & HINTZE, T.H. (1998). Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation, 97, 576-580.